Please note that following on from information provided to NICE by the company in June 2011, the appraisal of Desferrioxamine, deferiprone and deferasirox for the treatment of chronic iron overload [ID350] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
|
Status
|
Discontinued
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
TA
|
| ID number |
350
|
| Referral date |
01 July 2010 |
|
Topic area
|
- Blood and immune system
- Endocrine, nutritional and metabolic
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: |
TBC |
| 1st appraisal committee meeting: |
TBC |
Project Team
| Communications manager: |
Shalu Kanal |
| Executive Lead: |
Peter Littlejohns |
| Project manager: |
Jeremy Powell
|
| Technical Lead: |
Raisa Sidhu |
Email enquiries